The Psychiatric Pipeline in Review: Quarter 2, 2025
Psychiatric Times
JULY 7, 2025
MindMed initiated a phase 3 study of MM120 for major depressive disorder, with results expected in the second half of 2026. If approved, Bysanti could be available for sale in the US in 2026. Results are expected in 2026. Topline data from Part A of the study is expected to be released in the second half of 2026.
Let's personalize your content